CEOCFO-Press Release

Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas.
Press Release - Concert Pharmaceuticals, Inc. (Private)
	Concert is a big idea. Our technology has very broad applicability to a wide range of novel best-in-class and first-in-class therapeutic agents, some of which we have discussed today. We have the potential to make a real difference in terms of healthcare. There are relatively few companies being funded at present that have that potential. Concert has developed in-house the world leading expertise in the use of deuterium chemistry and we believe that we have the ability and capacity to apply that expertise to the creation of... - Dr. Roger Tung (Interview published February 3, 2012)
The Most Powerful Name In Corporate News and Information.
CURRENT ISSUE \| COVER ARCHIVES \| INDEX \| CONTACT \| FINANCIALS \| MARKETING SERVICES \| HOME PAGE

CEOCFO- Members Login Become A Member!	March 27, 2012 7:01 ET Concert Pharmaceuticals to Present at the Needham 2012 Healthcare Conference on April 3, 2012 LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the Needham 2012 Healthcare Conference on Tuesday, April 3, 2012 at 10:00 a.m. ET. The conference will be held April 3-4, 2012 at New York Palace Hotel. About Concert Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE Platform™ (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Concert’s approach leverages decades of pharmaceutical and clinical experience to reduce the time, risk and expense needed to create important new medicines. The company has a broad research pipeline encompassing many therapeutic areas including antiviral disease, renal disease, hematologic disorders, and CNS disorders, among others. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com. Concert Pharmaceuticals, the CoNCERT logo and the DCE Platform are trademarks of Concert Pharmaceuticals, Inc. Contacts Concert Pharmaceuticals, Inc. Justine E. Koenigsberg, 781-674-5284 Senior Director, Corporate Communications and Investor Relations Source: Concert Pharmaceuticals, Inc.

ceocfointerviews.com does not purchase or make
recommendation on stocks based on the interviews published.

Concert Pharmaceuticals to Present at the Needham 2012 Healthcare Conference on April 3, 2012